General Proximity is a seed-stage startup committed to advancing drug discovery through its unique OmniTAC platform, which facilitates the development of bifunctional medicines targeting difficult or "undruggable" proteins. The company addresses longstanding challenges in pharmacology by creating molecules that harness existing cellular mechanisms, allowing for new therapeutic avenues. With a focus on collaboration and innovation, General Proximity seeks to pioneer new frontiers in cancer biology and beyond. The team values high levels of agency, enthusiasm, and resilience, fostering an environment where independent thinking and emotional investment in creating life-saving medicines are paramount. By prioritizing clear communication and a supportive culture, General Proximity prepares its team for the complexities and demands of drug discovery, aiming to contribute significantly to healthcare solutions.